Market Overview

Goldman Sachs Upgrades Vertex Pharmaceuticals To Buy

Related VRTX
Barron's Picks And Pans: Drug Stocks, Hanesbrands, Wabtec And More
Stocks To Watch In Market Weakness
Perceptive Advisors Llc Buys Alnylam Pharmaceuticals Inc, Global Blood Therapeutics Inc, ... (GuruFocus)

Analysts at Goldman Sachs upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) from Neutral to Buy.

The target price for Vertex Pharmaceuticals has been raised from $109 to $131.

Vertex Pharma shares have gained 16.00% over the past 52 weeks, while the S&P 500 index has surged 20.10% in the same period.

Vertex Pharmaceuticals' shares rose 0.22% to $95.25 in pre-market trading.

Latest Ratings for VRTX

Mar 2017BMO CapitalUpgradesMarket PerformOutperform
Mar 2017JMP SecuritiesUpgradesMarket PerformMarket Outperform
Dec 2016OppenheimerInitiates Coverage OnPerform

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Goldman SachsUpgrades Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!